source
- Osivax’s flu vaccine OVX836 misses primary efficacy goal in phase 2b trialOsivax announced that its influenza A vaccine candidate OVX836 failed to meet the primary efficacy endpoint in a phase 2b trial involving 2,850 healthy adults in Europe. The trial showed a vaccine…
- Webinar Explores How US Biotechs Can Compete and Collaborate with China’s Growing IndustryBioSpace is hosting a webinar titled "The China question: Can US biotechs lead as investment heads east?" on October 15, 2026. The event will feature a panel of experts who will discuss how China i…